Shanghai EpimAb Biotherapeutics Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2015)

Organization Overview

First Clinical Trial
2018
NCT03797391
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Shanghai EpimAb Biotherapeutics Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (4)

emb-01 (3 trials)

emb-02 (1 trial)

emb-06 (1 trial)

osimertinib (tagrisso) (1 trial)

Drugs in Phase 1 Trials (2)

emb07 (1 trial)

emb-09 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6